SCHEMBL13183752

SCHEMBL13183752

Cc1cccc(Cc2cnc(C)s2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ HPGD P15428 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ ABL1 P00519 1/20 0.52
▸ LMNA P02545 4/20 0.51
▸ OPRK1 P41145 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ CCR6 P51684 1/20 0.51
▸ GPR55 Q9Y2T6 1/20 0.51
▸ SIRT2 Q8IXJ6 1/20 0.48
▸ CYP11B1 P15538 1/20 0.48
▸ CYP11B2 P19099 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.47
▸ TAAR1 Q96RJ0 1/20 0.41
▸ LTA4H P09960 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3144357 0.84 EPHX2 (0.54) MAPTMEN1KMT2AHPGDKDM4E
SCHEMBL10272444 0.82 LMNA (0.64) MAPTMEN1KMT2AHPGDKDM4E
SCHEMBL13183550 0.81 MAPT (0.50) MAPTMEN1KMT2AHPGDKDM4E
SCHEMBL13844983 0.80 ABL1 (0.53) ABL1HTR2CHTR2B
SCHEMBL14076496 0.79 LMNA (0.48) MAPTMEN1KMT2AKDM4ENPC1
SCHEMBL16598125 0.77 TBXAS1 (0.46) ALDH1A1LMNACYP11B1CYP11B2TDP1
SCHEMBL13142435 0.75 SLC6A3 (0.43) MAPTALDH1A1LMNAHTTCYP11B1
SCHEMBL21890681 0.75 CYP11B1 (0.44) MAPTMEN1KMT2AHPGDKDM4E
SCHEMBL14259479 0.74 TP53 (0.46) MAPTMEN1KMT2AHPGDKDM4E
SCHEMBL13183620 0.73 IDO1 (0.43) MAPTMEN1KMT2AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420686-B2 Linked diimidazole antivirals ENANTA PHARMACEUTICALS, INC. (US) 2013-04-16 — — US disclosed
US-20100226882-A1 LINKED DIIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC. 2010-09-09 — — US disclosed
WO-2010096462-A1 LINKED DIIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC (US) 2010-08-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226882-A1 LINKED DIIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, MAVS MAPT 3992/4885MEN1 4813/4885KMT2A 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback